KB-1851

Torudokimab

60900

Background of Torudokimab

IL-33 is an alarmin, acts locally at the sites of inflammation and is upstream of the canonical type 2 cytokines. Its neutralization may have the potential for efficacy in patients with allergic diseases. Therefore, the development of a neutralizing antibody recognizing human IL-33 was undertaken resulting in torudokimab, which began a first-in-human study in November 2017 (NCT03343587) and a Phase 2 study in atopic dermatitis in February 2019 (NCT03831191) to test the hypothesis that IL-33 neutralization could be of therapeutic use in atopic dermatitis and other allergic diseases.

Specifications

Catalog Number	KB-1851
Antibody Name	Torudokimab
Isotype	Human IgG4-S228P,kappa
FC Muations	S228P/F234A/L235A/K441del
Target	IL33
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Okragly AJ, Corwin KB, Elia M, He D, Schroeder O, Zhang Q, Shiyanova T, Bright S, Dicker SB, Chlewicki L, Truhlar SME, Davies J, Patel CN, Benschop RJ. Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33. J Inflamm Res. 2021 Aug 11;14:3823-3835.